Ifosfamide in soft tissue sarcoma.

Ifosfamide, a congener of Cyclophosphamide, was originally introduced into clinical practice in 1971, but has not been widely used because of severe dose limiting urotoxicity, particularly when used as a single agent in large doses. A resurgence of interest in Ifosfamide followed the demonstration that urotoxicity could be lessened or abrogated by fractionated administration or, more effectively, by the concurrent administration of sulphahydryl compound mesna (2mercaptoethanesulphonate), a highly uroprotective agent. It is now clear that Ifosfamide has a broad spectrum of activity in human cancer . This study reports our experience with Ifosfamide in patients with soft tissue sarcomas.